BioXcel Therapeutics Gestion
Gestion contrôle des critères 3/4
Le PDG BioXcel Therapeutics est Vimal Mehta, nommé en Apr2017, a un mandat de 9.17 ans. La rémunération annuelle totale est $ 971.60K, composée du salaire de 72.7% et des bonus 27.3%, y compris les actions et options de la société. détient directement 0.23% des actions de la société, d'une valeur de $ 74.60K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.4 ans et 7.9 ans.
Informations clés
Vimal Mehta
Directeur général
US$971.6k
Rémunération totale
| Pourcentage du salaire du PDG | 72.72% |
| Durée du mandat du directeur général | 9.2yrs |
| Propriété du PDG | 0.2% |
| Durée moyenne d'occupation des postes de direction | 5.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.9yrs |
Mises à jour récentes de la gestion
Recent updates
BTAI: At Home Agitation Franchise Will Unlock Future Upside Potential
Analysts have lifted their price target on BioXcel Therapeutics stock to $17, up from $14, citing what they view as a differentiated at-home agitation franchise, expanding BXCL501 neuropsychiatry options, and a wide gap between the current enterprise value and the company's risk adjusted cash flow potential. What's in the News BioXcel Therapeutics reported new positive data from the Phase 3 SERENITY At-Home trial of BXCL501 in agitation tied to bipolar disorders or schizophrenia in the at home setting, with exploratory analyses showing reduced agitation versus placebo across mild, moderate, and severe baseline symptoms, and benefit observed with repeated dosing.BTAI: At Home Agitation Opportunity Will Drive Future Upside Despite Dilution
Analysts have reset BioXcel Therapeutics' blended price target closer to $6, reflecting recent equity dilution while still pointing to what they view as attractive upside from the company's differentiated at home agitation franchise and expanding BXCL501 neuropsychiatry opportunities. Analyst Commentary Recent Street commentary on BioXcel Therapeutics centers on how to balance dilution driven pressure on the share price with what analysts see as meaningful potential around the BXCL501 franchise and the broader neuropsychiatry pipeline.BTAI: At Home Agitation Franchise Will Drive Future Repricing Despite Dilution
Narrative Update The analyst fair value estimate for BioXcel Therapeutics has been adjusted slightly to $14.00 from $14.25, as analysts weigh the recent equity dilution against ongoing views that BXCL501's at-home agitation use and broader neuropsychiatry potential support a higher upside than current trading levels suggest. Analyst Commentary Recent Street research highlights a split view on BioXcel Therapeutics, with some analysts focused on the long-term potential of BXCL501 and others more focused on balance sheet pressure from equity issuance.BTAI: At Home Agitation Expansion Will Drive Repricing Despite Dilution Concerns
Analysts now set an updated $14.25 price target for BioXcel Therapeutics, refining their outlook as they weigh enthusiasm around the at-home agitation franchise and expanding BXCL501 options against recent and expected equity dilution. Analyst Commentary Recent Street research reflects a split view on BioXcel Therapeutics, with some analysts emphasizing upside tied to the at-home agitation portfolio and others focusing more on the impact of equity dilution on upside potential.BTAI: At Home Agitation sNDA Will Drive Repricing Despite Equity Dilution Concerns
Analysts have trimmed their fair value estimate for BioXcel Therapeutics from $15.25 to $14.25, reflecting a lower price target after recent Street research highlighted equity dilution as a key concern. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after the price target adjustment to US$6, suggesting they believe current valuation already reflects a good portion of the equity dilution risk.BTAI: At Home Agitation sNDA And Planning Will Drive Repricing Potential
Analysts kept their $15.25 price target for BioXcel Therapeutics unchanged, citing relatively steady modeled fair value, a similar discount rate and revenue outlook, and only modest tweaks to profit margin and future P/E assumptions. What's in the News Completed an updated market opportunity assessment for IGALMI for acute agitation in bipolar disorder or schizophrenia in the at home setting, using insights from the SERENITY At Home study to guide launch planning.BTAI: At Home Agitation Use Expansion Will Drive Repricing Potential
Analysts now see fair value for BioXcel Therapeutics at US$15.25, down from US$16.75. This reflects updated assumptions for growth, profitability and a higher future P/E multiple in their models.BTAI: At Home Agitation Approval Effort Will Drive Repricing Potential
Analysts have revised their price target for BioXcel Therapeutics to US$16.75, with the change largely tied to updated assumptions for the discount rate, profit margin outlook, and a slightly lower future P/E multiple. What's in the News Submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for IGALMI for at home treatment of agitation tied to bipolar disorders or schizophrenia, aiming to expand use beyond healthcare provider supervised settings where there are currently no FDA approved options (Key Developments).BTAI: At Home Agitation sNDA And Safety Data Will Drive Repricing
Analysts have modestly reset their price target for BioXcel Therapeutics to US$16.75. This reflects updated assumptions around discount rate, profit margin, and future P/E that keep their fair value view broadly unchanged.BTAI: At Home Agitation Approval Pathway Will Drive Bullish Repricing
Narrative Update on BioXcel Therapeutics Analysts have modestly lifted their price target on BioXcel Therapeutics, citing a reaffirmed fair value estimate near $16.75 per share, supported by stable long term growth and profitability assumptions, despite a slightly higher discount rate and modestly richer projected valuation multiples. What's in the News Shareholders are scheduled to vote at the December 12, 2025 AGM on an amendment to the certificate of incorporation that would enable a reverse stock split, which may reflect efforts to maintain listing compliance and improve share price optics (company filing).BTAI: Phase 3 At Home Agitation Data Will Drive Bullish Repricing
Analysts have raised their price target on BioXcel Therapeutics to $4 from $2, citing stronger long term risk adjusted sales potential for BXCL501 supported by positive Phase 3 SERENITY At Home data, while still flagging financing uncertainty. Analyst Commentary Analysts updating their models following the SERENITY At Home readout are highlighting both improved long term revenue potential and persistent execution risks that temper the valuation upside.BTAI: Strong Phase 3 Study Results Will Drive Further Market Momentum
Analysts have lowered their fair value estimate for BioXcel Therapeutics from $23.75 to $16.75 per share, citing improved long-term revenue projections and profit margins. This outlook is balanced by ongoing uncertainties related to the company’s financing strategy.BTAI: Upcoming Regulatory Milestones Will Drive Momentum Following Key Phase 3 Success
Analysts have increased their fair value price target for BioXcel Therapeutics from $19 to $23.75, citing improved revenue growth expectations, a higher profit margin forecast, and optimism following positive BXCL501 study results as well as expanded indications. Analyst Commentary Recent analyst updates reflect a mix of optimism and ongoing caution surrounding BioXcel Therapeutics following positive developments for BXCL501 and improving financial projections.
BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons
Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships.Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now
Key Insights BioXcel Therapeutics will host its Annual General Meeting on 10th of June CEO Vimal Mehta's total...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$75m |
| Dec 31 2025 | US$972k | US$707k | -US$70m |
| Sep 30 2025 | n/a | n/a | -US$68m |
| Jun 30 2025 | n/a | n/a | -US$51m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$1m | US$1m | -US$60m |
| Sep 30 2024 | n/a | n/a | -US$71m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$153m |
| Dec 31 2023 | US$5m | US$1m | -US$179m |
| Sep 30 2023 | n/a | n/a | -US$212m |
| Jun 30 2023 | n/a | n/a | -US$203m |
| Mar 31 2023 | n/a | n/a | -US$187m |
| Dec 31 2022 | US$5m | US$944k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$137m |
| Jun 30 2022 | n/a | n/a | -US$122m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | US$9m | US$917k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$100m |
| Mar 31 2021 | n/a | n/a | -US$94m |
| Dec 31 2020 | US$10m | US$890k | -US$82m |
| Sep 30 2020 | n/a | n/a | -US$69m |
| Jun 30 2020 | n/a | n/a | -US$54m |
| Mar 31 2020 | n/a | n/a | -US$41m |
| Dec 31 2019 | US$2m | US$459k | -US$33m |
Rémunération vs marché: La rémunération totale de Vimal ($USD 971.60K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 647.34K ).
Rémunération et revenus: La rémunération de Vimal a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Vimal Mehta (64 yo)
Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 9.2yrs | US$971.60k | 0.23% $ 74.6k | |
| Senior VP & CFO | 8.7yrs | US$394.65k | 0.085% $ 28.1k | |
| Senior VP | 5.4yrs | US$432.58k | 0.087% $ 28.7k | |
| Executive VP & Chief Scientific Officer | 2.5yrs | US$1.15m | 0.085% $ 28.0k | |
| Acting Chief Commercial Officer | less than a year | pas de données | pas de données | |
| Vice President of Clinical Development | no data | pas de données | pas de données |
Gestion expérimentée: L'équipe dirigeante de BTAI est chevronnée et expérimentée (5.4 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 9.2yrs | US$971.60k | 0.23% $ 74.6k | |
| Member of Advisory Board | no data | pas de données | pas de données | |
| Independent Chairman & Lead Director | 9.2yrs | US$130.00k | 0.038% $ 12.5k | |
| Member of Clinical Advisory Board | 7.9yrs | pas de données | pas de données | |
| Member of Clinical Advisory Board | 7.3yrs | pas de données | pas de données | |
| Member of Clinical Advisory Board | 7.3yrs | pas de données | pas de données | |
| Member of Clinical Advisory Board | 7.9yrs | pas de données | pas de données | |
| Member of Clinical Advisory Board | 7.9yrs | pas de données | pas de données | |
| Member of Clinical Advisory Board | 7.3yrs | pas de données | pas de données | |
| Independent Director | 8.8yrs | US$92.50k | 0% $ 0 | |
| Member of Advisory Board | no data | pas de données | pas de données | |
| Member of Clinical Advisory Board | 7.9yrs | pas de données | pas de données |
Conseil d'administration expérimenté: Les membres du conseil d'administration de BTAI sont considérés comme expérimentés (ancienneté moyenne 7.9 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/09 11:32 |
| Cours de l'action en fin de journée | 2026/06/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
BioXcel Therapeutics, Inc. est couverte par 9 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |